Bio-Techne (MIL:1TECH) Long-Term Debt: €173 Mil (As of Mar. 2026)


MIL:1TECH Bio-Techne Corp MIL:1TECH
59 GF Score
Price €62.06
GF Value €77.14
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Long-Term Debt?

Bio-Techne MIL:1TECH 59 Long-Term Debt is €173 Mil as of Mar. 2026. GuruFocus rates MIL:1TECH with a GF Score™ of 59/100 and a GF Value™ of €77.14 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Bio-Techne's Long-Term Debt for the quarter that ended in Mar. 2026 was €173 Mil.

Bio-Techne's quarterly Long-Term Debt declined from Sep. 2025 (€256 Mil) to Dec. 2025 (€222 Mil) and declined from Dec. 2025 (€222 Mil) to Mar. 2026 (€173 Mil).

Bio-Techne's annual Long-Term Debt declined from Jun. 2023 (€323 Mil) to Jun. 2024 (€296 Mil) but then increased from Jun. 2024 (€296 Mil) to Jun. 2025 (€300 Mil).

Bio-Techne  (MIL:1TECH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bio-Techne Long-Term Debt Related Terms

Bio-Techne Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Long-Term Debt Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 272.93 230.27 323.05 296.35 299.98

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 305.25 299.98 255.60 222.04 173.00
MIL:1TECH
59GF Score
Bio-Techne Corp MIL:1TECH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €173 Mil mean?
Bio-Techne (MIL:1TECH) has a Long-Term Debt of €173 Mil as of Mar. 2026.
Is Bio-Techne's Long-Term Debt too high?
Bio-Techne's current Long-Term Debt is €173 Mil. Overall, Bio-Techne has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Long-Term Debt compare to ARWR and CYTK?
Bio-Techne's Long-Term Debt of €173 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bio-Techne's current Long-Term Debt is €173 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Modestly Undervalued. The stock's GF Value™ is €77.14, compared to a current price of €62.06 — trading 19.5% below its estimated fair value. The current Long-Term Debt is €173 Mil. Bio-Techne's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Long-Term Debt is €173 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MIL:1TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.06 is trading 19.5% below its estimated GF Value™ of €77.14. GuruFocus considers Bio-Techne to be Modestly Undervalued.

Key valuation signals for MIL:1TECH:

  • Long-Term Debt: €173 Mil
  • GF Value™: €77.14 vs. price of €62.06 (19.5% below fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
59GF Score

Get the complete analysis for MIL:1TECH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.06
Price
€77.14
GF Value